Aptamers in cancer immunotherapy and diagnosis: engineering principles, biomedical applications, and translational challenges
Aptamers are chemically synthesized single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) ligands that fold into defined three-dimensional structures and recognize proteins, glycans, metabolites, extracellular vesicles (EVs), and whole-cell phenotypes with high affinity and specificity. In oncology, aptamers are no longer regarded merely as antibody substitutes. Their chemical tunability, structural programmability, and compatibility with nucleic acid circuits allow them to function as immune modulators, cell-bridging scaffolds, drug and nucleic acid delivery vehicles, nanostructure components, imaging probes, and signal-amplifying biosensors. This review summarizes recent progress in aptamer-enabled cancer immunotherapy and diagnosis, with emphasis on engineering principles, biomedical applications, and translational challenges. We first discuss aptamer selection, chemical stabilization, pharmacokinetic optimization, and architectural engineering. We then review how aptamers modulate major immune-cell compartments, including T cells, natural killer cells, regulatory T cells, dendritic cells, macrophages, and myeloid-derived suppressor cells. Next, we examine aptamer-based combination strategies, including aptamer-drug conjugates, aptamer-nucleic acid chimeras, DNA frameworks, biomimetic nanocarriers, engineered bacteria, and theranostic hydrogels. We also summarize diagnostic applications in biomarker detection, extracellular vesicle profiling, circulating tumor cell analysis, tissue-marker assessment, treatment-response monitoring, and aptamer-enabled biomarker discovery. Finally, we discuss the major barriers that continue to limit clinical translation, including nuclease susceptibility, rapid renal clearance, tissue penetration, endosomal escape, product complexity, assay standardization, clinical validation, and competition with established antibody-based technologies. Overall, aptamers are best positioned not as broad replacements for antibodies, but as programmable oncology modules for applications in which synthetic control, tunable binding, nucleic acid compatibility, and signal amplification provide clear clinical value.
Authors
- Chunmei Xu
- Yuan Guo (ORCID: https://orcid.org/0000-0002-3850-4664)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Frontiers in Molecular Biosciences
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fmolb.2026.1994248
- Primary Topic
- Advanced biosensing and bioanalysis techniques
- Type
- article
- Field-Weighted Citation Impact
- 0.00